COMPRESSED MATTER: WHY YOUNGER & FASTER MEANS BIGGER

COMPRESSED MATTER: WHY YOUNGER & FASTER MEANS BIGGER

While the US population is 500% bigger than the UK’s, size alone does not account for the discrepancy in economic success of the top 5 stocks listed in the US and the UK. Selecting a sector where it is possible to create highly exponential rates of growth, so-called hyperscaling, is perhaps an even more important factor.

While the US population is 500% bigger than the UK’s, size alone does not account for the discrepancy in economic success of the top 5 stocks listed in the US and the UK. Selecting a sector where it is possible to create highly exponential rates of growth, so-called hyperscaling, is perhaps an even more important factor.

This is why the five biggest US stocks by market cap are more than 12x larger than the UK’s but one fifth of the average age (the average age of the UK’s top five is c 150 years versus 32 years in the US). Also, the average market cap of the US top five is US$1.4tn, while no single company listed in the UK is worth more than a tenth of that.

Company Market cap (US$tn) Age Market cap (US$tn) Age
Apple Inc 2.02 45 Unilever 0.14 92
Microsoft Corp 1.71 46 AstraZeneca 0.12 108
Amazon.com Inc 1.5 27 HSBC 0.14 136
Alphabet Inc 1.38 23 Rio Tinto 0.1 148
Facebook Inc 0.73 17 Diageo 0.1 272
Total 7.34 158 0.58 756
Average 1.47 31.6 0.12 151

Source: Thomson Reuters at 5 March 2021. Note: *Ages based on the oldest direct ancestor of present legal entity.

To quote Lord Hill’s report of last week, ‘the most significant companies listed in London are either financial or more representative of the ‘old economy’ than the companies of the future.’

What does this mean? Could the UK change its trajectory? If so, how? We would very much like to hear your thoughts on our Twitter and LinkedIn feeds. Our analysts will be joining the discussion as well.

Latest

news

Milosz Papst in Investors’ Chronicle

news

Neil Shah in AskTraders

news

Jonathan Day in AskTraders

news

Milosz Papst in Investors’ Chronicle

Seven things every investor should know about SIGA technologies & biological weapons

Nasdaq-listed SIGA Technologies (SIGA) is a profitable pharmaceuticals business, focused on safeguarding against viruses as biological weapons. We value SIGA, an Edison client, at US$968m or $12.61/ per share.

Continue Reading
Cookie Policy Overview
Edison Group

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping us understand which section of the website you find more interesting and useful. See our Cookie Policy for more information.

Strictly necessary and functional

These cookies are used to deliver our website and content. Strictly necessary cookies relate to our hosting environment, and functional cookies are used to facilitate social logins, social sharing and rich-media content embeds.

Advertising

Advertising Cookies collect information about your browsing habits such as the pages you visit and links you follow. These audience insights are used to make our website more relevant.

Performance

Performance Cookies collect anonymous information designed to help us improve the site and respond to the needs of our audiences. We use this information to make our site faster, more relevant and improve the navigation for all users.